The association between tocilizumab and the secondary bloodstream infection maybe nonsignificant in hospitalized patients with SARS-CoV-2 infection: A cohort study

Background: Immunomodulatory agents, such as tocilizumab (TCZ), exert promising effects against SARS-CoV-2 infection. However, growing evidence indicates that using TCZ may carry higher risks of secondary bloodstream infection (sBSI). This study determined whether TCZ is associated with an increased...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	De-En Lu, Tsong-Yih Ou, Jyun-Wei Kang, Jie Ywi Ong, I-Ju Chen, Chih-Hsin Lee, Ming-Chia Lee
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2024-02-01
Serier:	Journal of Microbiology, Immunology and Infection
Fag:	SARS-CoV-2 infection Secondary bloodstream infections Tocilizumab
Online adgang:	http://www.sciencedirect.com/science/article/pii/S1684118223002025
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!